Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Posted on by

PT-112’s mechanism of action promotes immunogenic cancer cell death through ribosomal biogenesis inhibition and organelle stress NEW YORK, Oct. 14, 2023 /PRNewswire/ — Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.